Beyond the cholinergic hypothesis: The effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 9, Issue SUPPL. 2, 1998, Pages 8-14

  Kaufer, Daniel ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Alzheimer's disease; Apathy; Behaviour; Cholinesterase inhibitor; Depression; Donepezil; Hallucinations; Metrifonate; Neuropsychiatric; Tacrine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; HALOPERIDOL; METRIFONATE; PHYSOSTIGMINE; TACRINE;

ALZHEIMER DISEASE; APATHY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; MOTOR DYSFUNCTION; MULTICENTER STUDY; NEUROLOGIC DISEASE; PERSONALITY DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031815934     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051193     Document Type: Conference Paper

References (58)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
2. Cummings JL, Victoroff JI: Noncognitive neuropsychiatric syndromes in Alzheimer's disease. Neuropsychiatr Neuropsychol Behav Neurol 1990;3:140-158.
3. Mega MS, Cummings JL, Fiorello T, Gornbein J: The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46;130-135.
4. Teri L, Larson E, Reifler BV: Behavioral disturbances in dementia of the Alzheimer's type. J Am Geriatr Soc 1988;36:1-6.
5. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotis A: Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. J Clin Psychiatry 1987;48:9-15.
6. Mangone CA, Sanguinetti RM, Baumann PD, Gonzalez RC, Pereyra S, Bozzola FG, Gorelick PB, Sica RE: Influence of feelings of burden on the caregiver's perception of the patient's functional status. Dementia 1993;4:287-293.
7. Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, Masterman D, MacMillan A, Ketchel P, DeKosky S: Assessing the impact of neuropsychiatric disturbances in Alzheimer's disease: The Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 1998 (in press).
8. Steele C, Rovner B, Chase GA, Folstein M: Psychiatric problems and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990;147:1049-1051.
9. O'Donnell BF, Drachman DA, Barnes HJ, Petersen KE, Swearer JM, Lew RA: Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiat Neural 1992;5:45-52.
10. Mittleman MS, Ferris SH, Shulman E, Steinberg G, Levin B: A family intervention to delay nursing home placement of patients with Alzheimer's disease: A randomized controlled trial. JAMA 1996;276:1725-1731.
11. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR: Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982;215:1237-1239.
12. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J [Clin Res] 1978;2:1457-1459.
13. Collerton D: Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience 1986;19:1-28.
14. Bartus RT, Dean III RL, Beer B, Lippa A: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-417.
15. Perry EK: The cholinergic hypothesis - ten years on. Brit Med Bull 1986;42:63-69.
16. Knapp MJ, Knopman DS, Solomon PR, Tacrine Study Group: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271: 985-991.
17. Rogers SL, Friedhoff LT, Donepezil Study Group: The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:292-303.
18. Palmer AM, DeKosky ST: Monoamine neurons in aging and Alzheimer's disease. J Neural Transm [Gen Sect] 1993;91:135-159.
19. Raskind MA, Peskind ER: Neurologic bases of noncognitive behavioral problems in Alzheimer's disease. Alz Dis Assoc Disord 1994;8(suppl 3):54-60.
20. Cummings JL, Kaufer DI: Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology 1996;47:876-883.
21. Cummings JL, Gorman DG, Shapira J: Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiat 1993;33:536-541.
22. Gorman DG, Read SR, Cummings JL: Cholinergic therapy of behavioral disturbances in Alzheimer's disease. Neuropsychiatr Neuropsychol Behav Neurol 1993;6:229-234.
23. Kaufer DI, Cummings, JL, Christine D: Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study. J Geriatr Psychiat Neurol 1996;9:1-6.
24. Raskind MA, Sadowsky CH, Sigmund WR, Beitler PJ, Auster SB: Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer's disease. Arch Neurol 1997;54:836-840.
25. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975;12:189-198.
26. Rosen WG, Terry RD, Fuld P, Katzman R, Peck A: Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488.
27. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
28. Alhainen K, Helkala E-L, Riekkinen P: Psychometric discrimination of tetrahydroaminoacridine responders in Alzheimer's patients. Dementia 1993;4:54-58.
29. Sahakian BJ, Owen AM, Morant NJ, Eagger SA, Boddington S, Crayton L, Crockford HA, Crooks M, Hill K, Levy R: Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: Assessment of attentional and mnemonic function using CANTAB. Psychopharmacology 1993;110: 395-401.
30. Mesulam M-M: Large-scale neurocognitive networks and distributed processing for attention, language, and memory. Ann Neurol 1990; 28:597-613.
31. Perry EK, Perry RH: Acetylcholine and hallucinations: Disease-related compared to drug-induced alterations in human consciousness. Brain Cognition 1995;28:240-258.
32. Smith G: Animal models of Alzheimer's disease: Experimental cholinergic denervation. Brain Res Rev 1988;13:103-118.
33. Decker MW, McGaugh JL: The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 1991;7:151-168.
34. Sunderland T, Molchan SE, Little JT, Bahro M, Putnam KT, Weingartner H: Pharmacologic challenges in Alzheimer's disease and normal controls: Cognitive modeling in humans. Alz Dis Assoc Disord 1997;11:S23-26.
35. Samuel W, Henderson VE, Miller CE: Severity of dementia in Alzheimer's disease and neurofibrillary tangles in multiple brain regions. Alz Dis Assoc Disord 1991;5:1-11.
36. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW: The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1991;1:103-116.
37. Braak H, Braak E: Neuropathological staging of Alzheimer's-related changes. Acta Neuropathol 1991;82:239-259.
38. Sultzer DL, Mahler ME, Mandelkern MA, Cummings JL, Van Gorp WG, Hinkin CH, Berisford MA: The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease. J Neuropsychiat Clin Neurosci 1995;7:476-484.
39. Craig AH, Cummings JL, Fairbanks L, Itti L, Miller BL, Li J, Mena I: Cerebral blood flow correlates of apathy in Alzheimer's disease. Arch Neurol 1996,53:1116-1120.
40. Cummings JL: Personality alterations in Alzheimer's disease: Assessment and characterization. Bull Clin Neurosci 1989;54:80-87.
41. Kaufer DI, Cummings JL: Personality alterations in degenerative brain disorders: in Ratey J (ed): Neuropsychiatry of Personality Disorders. Cambridge, MA, Blackwell Scientific Publications, 1995, pp 172-209.
42. Kaufer DI, Cummings JL, Christine D: Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: Relationship to dementia severity. J Neuropsychiat Clin Neurosci 1988, in press.
43. Janowsky DS, El-Yousef K, Davis JM: Parasympathetic suppression of manic symptoms by physostigmine. Arch Gen Psychiat 1973;28: 542-547.
44. Cummings JL: Frontal-subcortical circuits and human behaviour. Arch Neurol 1993;50:873-880.
45. Palmer AM, Stratmann GC, Procter AW, Bowen DM: Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann Neurol 1988;23:616-620.
46. Marin RS: Differential diagnosis and classification of apathy. Am J Psychiat 1990;147:22-47.
47. Wragg RE, Jeste DV: Overview of depression and psychosis in Alzheimer's disease. Am J Psychiat 1989;146:577-587.
48. Cummings JL: Psychosis in neurologic disease: Neurobiology and pathogenesis. Neuropsychiat Neuropsychol Behav Neurol 1992;5:144-150.
49. Langlais PJ, Thal LJ, Hansen L, Galasko D, Alford M, Masliah E: Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology 1993;43:1927-1934.
50. Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, Fairbairn AF, Ince PG, Morris CM, Cheng AV: Cholinergic transmitter and neurotrophic activities in Lewy body dementia: Similarity to Parkinson's and distinction from Alzheimer disease. Alz Dis Assoc Disord 1993;7:69-79.
51. Perry EK, Marshall E, Kerwin JM, Smith CJ, Jabeen S, Cheng AV, Perry RH: Evidence of a monoaminergic:cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 1990;55:1454-1456.
52. Levy R, Sahakian B: Alzheimer's disease and Lewy body dementia. Br J Psychiat 1994;64: 268.
53. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller GL, Lovestone S, Collerton D, Jansen EN, Ballard C, de vos RA, Wilcock CK, Jellinger KA, Perry RH: Consensus guidelines for the clinical and pathological diagnosis of Dementia with Lewy bodies (DLB): Report on the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
54. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA 3d, Murphy DL: Anticholinergic sensitivity in patients with dementia of the Alzheimer's type and age-matched controls. Arch Gen Psychiat 1987;44:418-426.
55. Davis KL, Hollander E, Davidson M, Davis BM, Mohs RC, Horvath TB: Induction of depression with oxotremorine in patients with Alzheimer's disease. Am J Psychiat 1987;144: 468-471.
56. Penn RD, Martin EM, Wilson RS, Fox JH, Savoy SM: Intraventricular bethanecol infusion for Alzheimer's disease: Results of double-blind and escalating dose trials. Neurology 1988;38:219-222.
57. Schulz R, O'Brien AT, Bookwala J, Fleissner K: Psychiatric and physical morbidity effects of dementia caregiving: Prevalence, correlates, and causes. Gerontologist 1995;35:771-791.
58. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, Gracon S: Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality. Neurology 1996;47:166-177.